Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/28/2022* -- Results Q3 2022 -- 2.79 --
10/28/2022* 17:00 EST Earnings Call Q3 2022 -- -- --
07/28/2022 18:00 EST Earnings Call Q2 2022 -- -- --
07/28/2022 -- Results Q2 2022 3.38 2.77 21.93%
04/28/2022 -- Results Q1 2022 4.94 3.23 53.15%
04/28/2022 18:00 EST Earnings Call Q1 2022 -- -- --
02/10/2022 -- Results Q4 2021 3.21 2.87 11.81%
02/10/2022 18:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/28/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/28/2022
Beat/Miss Upgrade
Return Since -19.73%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
URL https://www.bio-rad.com
Investor Relations URL https://www.bio-rad.com/en-us/corporate?ID=1002
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style Mid Cap/Growth
Next Earnings Release Oct. 28, 2022 (est.)
Last Earnings Release Jul. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
15.01%
31.46%
30.94%
-2.70%
59.34%
57.54%
29.61%
-40.52%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.90%
-13.25%
65.19%
41.97%
11.23%
62.03%
63.10%
52.64%
-56.84%
23.70%
-12.16%
62.96%
-12.82%
71.85%
6.58%
55.36%
-32.77%
-38.80%
-12.10%
8.20%
-3.64%
-4.09%
40.66%
64.34%
-62.41%
5.60%
51.60%
-66.50%
98.53%
87.59%
140.4%
-36.86%
-69.81%
As of October 04, 2022.

Profile

Edit
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
URL https://www.bio-rad.com
Investor Relations URL https://www.bio-rad.com/en-us/corporate?ID=1002
HQ State/Province California
Sector Healthcare
Industry Medical Devices
Equity Style Mid Cap/Growth
Next Earnings Release Oct. 28, 2022 (est.)
Last Earnings Release Jul. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
GERM 869799.0 USD 3.93%
JSMD 4.784M USD 2.86%
GITUX 13.83M USD 2.56%
BAWAX 148.26M USD 2.51%
STSAX 20.01M USD 2.14%
MDEV 34154.00 USD 1.96%
PFUT 118800.0 USD 1.88%
WDSCX 28.52M USD 1.77%
AGTIX 32.05M USD 1.71%
FSMEX 98.57M USD 1.30%
IHI 53.30M USD 0.91%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter BIO Tweets